Docetaxel Inhibits Urethral Stricture Formation, an Initial Study in Rabbit Model

Delai Fu1, Tie Chong1, Hecheng Li1*, Huibo Zhang2, Ziming Wang1

1 Department of Urology, the Second Affiliated Hospital, School of Medicine, Xi’an Jiaotong University, Xi’an, Shaanxi, People’s Republic of China, 2 Department of Urology, the Affiliated Hospital of Shaanxi Traditional Chinese Medical Collage, Xianyang, Shaanxi, People’s Republic of China

Introduction

Urethral stricture is a frequent source of lower urinary tract disorders in men, characterized by narrowing of the urethra by a noncompliant section of urethral scar tissue. Currently the most common causes of urethral stricture are idiopathic, transurethral resection, urethral catheterization, pelvic fracture and hypospadias-surgery [1]. Urethral stricture is commonly treated with urethral dilation and visual internal urethrotomy, which can transiently improve urinary flow. Nevertheless, repeat instrumentation exacerbates scar formation complicating subsequent reconstruction [2], and repeated dilation or urethrotomy are neither clinically effective nor cost effective [3]. While urethroplasty offers a better cure rate [4], but it is not a routine operation and requires a certain expertise.

The pathogenesis of urethral stricture is a process of fibrosis, caused by excessive collagen synthesis and changes in the composition of the extracellular matrix. Varying degrees of spongiosis results in poorly compliant tissue and decreased urethral lumen caliber. Enlightened by the treatment of organ fibrosis, a few antifibrotic drugs were being used in trial of limiting urethral stricture formation, such as halofuginone, mitomycin C, bitoxin A, somatostatin analogue, glucocorticoid [5,6,7,8,9]. In the near decades, it is widely confirmed that rapamycin and paclitaxel eluting stent showed a satisfactory inhibiting effect on restenosis of coronary artery [10,11]. And our previous study had exposed rapamycin could inhibit urethral stricture formation in rabbits [12]. In this study, the role of docetaxel, a semi-synthetic analogue of paclitaxel, on inhibition of urethral stricture formation was investigated.

Abstract

Introduction: Urethral stricture, a frequent source of lower urinary tract disorders in men, is still a difficult problem for urologists. Based the anti-restenosis effect of paclitaxel on coronary artery, the role of docetaxel, a semi-synthetic analogue of paclitaxel, in limiting urethral stricture formation was studied.

Methods: Forty adult New Zealand male rabbits were involved in this study, which were randomly assigned into 3 groups, namely a high dose docetaxel (DH, 0.1 mg/d), a low dose docetaxel (DL, 0.01 mg/d) and a control (C) group, with 16, 16, 8 rabbits in each group, respectively. All animals underwent a 10 mm-long circumferential electrocoagulation of the bulbar urethra with a 13Fr pediatric resectoscope. Drugs were given by urethral irrigation daily and continuous for 28 days. Stricture formation was assessed by retrograde urethrography and videourethroscopy. Urethra pathology was evaluated by hematoxylin and eosin staining and Sirius red staining.

Results: At the end of this study, 15, 14 and 7 rabbits remained for evaluation in DH, DL and C group, respectively. Urethral diameters in DH, DL and C group were (7.17±1.63) mm, (6.55±0.62) mm, (3.23±1.36) mm, with a normal urethral diameter of (9.08±1.29) mm. Lumen reduction in DH, DL and C group were (36.93±11.58)%,(48.03±7.89)% and (84.66±14.95)%, respectively. Statistically difference could be found between every two groups (p<0.05) both in urethral diameters and in lumen reduction, except for compare of urethral diameters between DH and DL group. Histological examination confirmed mass fibrous tissue and collagen content at the stricture sit in C group, whereas less in docetaxel treated rabbits.

Conclusions: Docetaxel could limit urethral stricture formation, which may be due to inhibition of fibrous tissue and collagen expression. Docetaxel may become a new choice in the prevention of urethral stricture formation.

Materials and Methods

2.1 Ethics Statement

This study was carried out in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. The protocol was approved by the Committee on the Ethics of Animal Experiments of Xi’an Jiaotong University.
2.2 Animals and drugs
Totally 40 adult male New Zealand rabbits, aged 4 months and weighing (2.0±0.2) kg, were involved in this experiment, which were randomly allocated into 3 groups, namely a high dose docetaxel (DH), a low dose docetaxel (DL) and a control (C) group, with 16, 16, 8 rabbits in each group, respectively. The rabbits were kept in special cages in SPF environment, allowing free movement and free access to food and drink. Animals were raised in natural solar day-night cycles, fed with a special kind of solid fodder produced by Laboratory Animal Center of Xi’an Jiaotong University.

All process, including surgery, radiology, urethroscopy and sacrifice, was performed under diazepam and ketamine anesthesia, and all effort were made to minimize suffering. Docetaxel was gifted by Hengrui Pharmaceutical Company, ltd. Jiangsu province.

2.3 Production of urethral strictures
All rabbits were anaesthetized by premedication with i.v. diazepam (25 mg/kg) and i.v. Ketamine (2.5 mg/kg). For endoscopic procedures a 13Fr pediatric resectoscope (Hangzhou Hawk Optical Electronic Instruments Co., Ltd) was used. The rabbits were placed in a supine position. A 10 mm long circumferential electrocoagulation of the bulbar urethra was induced under sterile conditions. This procedure was performed distal to the verumontanum and always away from the external sphincter with a loop-shaped electrode at a power of 40 W [13]. Electrocoagulation was continued until blanching and ulceration of the mucosa occurred [13,14]. All electrocoagulation were done by the same urologist (Hecheng Li). The urine was not diverted deliberately and no antibiotics were given.

2.4 Drug administration
Drugs were given by retrograde urethral irrigation, once a day and last 28 days since the first day after electrocoagulation. The administration doses in DH, DL were 0.1 mg/day and 0.01 mg/day respectively and the irrigating volume was 10 ml every time for each animal. For rabbits in C group, 10 ml normal saline was injected instead.

2.5 Evaluation of urethral strictures
Twenty-eight days after electrocoagulation, to evaluate formation of urethral restriction, urethrograms and video-urethroscopy were used to measure the caliber of urethra on anesthetized animals. As described by Chong [12], meglumine amine (380 g/L) was used as contrast medium, which was slowly and directly injected into the urethra under X-ray monitoring. Retrograde urethraphy was continued until urethral lumen was manifested well. All process was done by the same urologist (Delai Fu). Referring to Meria [14], urethra 1 cm distal to the injured site was regarded as normal. Diameters of injured urethra and normal urethra were measured blindly. Urethral diameters and lumen reduction were compared among groups. Strictures were considered significant if the urethral lumen was decreased more than 50%. Video-urethroscopy was performed with a 13Fr pediatric resectoscope to further evaluate urethral stricture formation.

2.6 Histological evaluation
Rabbits were killed under anesthesia by intravenously injection 50 ml of air. The urethras from all rabbits were processed for histological examination as described by Anderson [15]. Initial tissue fixation was done before urethra was moved. Formaldehyde was injected into the urethra under a pressure of 1.8 kPa for 30 min. This was carried out by a special device, composed of a flexible pipe and a container. The pipe linked the orifice of urethra with the container. The container maintained liquid level of 18 cm above the operative platform, producing a pressure of 1.8 kPa. Then urethra was removed, further fixed in formaldehyde for 24 hours and embedded in paraffin. Sections were cut corresponding to the two distension sites longitudinally from the posterior wall of the urethra, perpendicularly to the wall, and stained with HE and sirius red. All slides were blindly reviewed by the same uropathologist.

2.7 Statistical analysis
Results of urethral diameter and lumen reduction are expressed as Mean ± SD. The amount of urethral fibrosis was evaluated as mild, moderate or severe. The One-Way ANOVA test was used for statistical analysis. A p value less than 0.05 was considered statistically significant.

Results
One rabbit in DH group, two rabbits in DL and one in C group died during anesthesia. Urethral bleeding was seen in almost all rabbits after electrocoagulation, but it was not severe and totally disappeared in 3 days. Thus, 15, 14 and 7 rabbits remained for evaluation in DH, DL and C group, respectively. No urinary retention occurred till the end of the study.

3.1 Formation of urethral stricture
Urethral diameters in DH, DL and C group were (7.17±1.63) mm, (6.55±0.62) mm, (3.23±1.36) mm, respectively, with a normal urethral diameter of (9.08±1.29) mm on the average. Statistically difference could be found between every two groups (p<0.01), except for compare of urethral diameters in DH and DL group (p=0.218).

According to urethral lumen reduction, all rabbits in C group had significant urethral stricture formation (lumen reduction > 50%), while 6 (37.5%) in DL group and none (0%) in DH group. The lumen cross section area decreased (84.66±14.95%) (rang, 60.94–96.48%) in C group, (48.03±7.89%) (rang, 34.22–62.00%) in DL group and (36.88±11.58%) (rang, 10.71–48.65%) in the DH group. Urethral lumen reduction was significantly more severe in C group than in the DH group (p<0.01) and in the DL group (p< 0.01). Lumen reduction was statistically more in the DL group than in the DH group (p = 0.010, Fig. 1, Table 1).

Based on urethroscopy, varying degree of bulbar urethra narrowing was found and the injured urethral surface had been covered by epithelium in all rabbits (Fig. 2).

3.2 Urethral histology
With H&E staining, a varying degree of fibrosis was found beneath the epithelium in differentially treated rabbits. For animals in DH group and DL group, this fibrosis was mainly localized in submucosa layer, while in control group, fibrosis distributed over submucosa and muscular layer (Fig. 3). Sirius Red staining showed light red staining of the urethral stricture site in DH and DL group, indicating relatively low collagen concentration. However, darker crimson staining was found in C group, indicating abundant collagen presence (Fig. 4).

Discussions
The present study was undertaken to investigate the effect of intraurethral injection of docetaxel on urethral stricture formation in rabbits. Our preliminary results demonstrated that docetaxel
could significantly inhibit urethral stricture formation. Urethral diameter in C group decreased to (3.23\(\pm\)1.36) mm from (9.08\(\pm\)1.29) mm in normal. Docetaxel inhibits this process with calibers of (7.17\(\pm\)1.63) mm and (6.55\(\pm\)0.62) mm in DH and DL group, respectively. Urethral lumen reduction in DH group decreased to less than 50%, while that in C group decreased more than 80%. The effect of docetaxel on inhibiting urethral stricture formation may mediate by inhibition of fibrosis formation and collagen coagulation. Although there are limitations to this pilot study, our results firstly suggest that intraurethral irrigation of docetaxel could obviously inhibit urethral stricture formation in rabbits.

Additionally and interestingly, no difference of urethral diameter was found between rabbits in DH and DL group \((p = 0.218)\), while judged with urethral cross-sectional area change, less lumen reduction in DH group than in DL group could be detected \((p = 0.010)\). A possible explanation of this distinction is the limited animal number and the deviation of urethral diameter between rabbits. Lumen reduction seems to be more sensitive than diameter in the evaluation of urethral stricture. A dose-dependent manner of docetaxel on inhibiting urethral stricture formation should and would appear with the increase of rabbit number.

Recent studies have shown that paclitaxel possess inhibitory effect on fibrosis diseases. In 2010, Zhang [16] et al first reported that intraperitoneal injection of low-dose paclitaxel (0.3 mg/kg, twice a week, sustained for 7 or 14 days) could reduce renal tubulointerstitial fibrosis in unilateral ureteral obstruction model in rat. At the same time, Zhou [17] et al cultured hepatic stellate cells in rat (RHSCs) and found paclitaxel, with a concentration of 200 nmol/L, could inhibit TGF-\(\beta\) induced RHSCs fibrosis. One year later, Sun [18] et al used the same dose and route of paclitaxel administration as Zhang [16] and indicated paclitaxel could ameliorate renal fibrosis with improvement in renal functions in a rat model of remnant kidney disease. A paclitaxel-eluting stent was even used in prevention of human malignant biliary obstruction [19]. Nevertheless, it was reported that prolonged chemotherapy treatment with paclitaxel/docetaxel was associated with canalicular stenosis, pulmonary fibrosis or scleroderma-like changes, albeit in only a small fraction of the patients [20,21,22]. It should be indicated that the inhibition of tumor cell proliferation can be achieved by much higher dosages of

| Group | n  | Urethral diameter (mm, mean ± SD) | Lumen reduction (%) |
|-------|----|---------------------------------|---------------------|
| DH    | 15 | 7.17\(\pm\)1.63*                | 36.93\(\pm\)11.58*  |
| Dl    | 14 | 6.55\(\pm\)0.62**               | 48.01\(\pm\)7.89**  |
| C     | 7  | 3.23\(\pm\)1.36***              | 84.66\(\pm\)14.95   |
| Normal| 36 | 9.08\(\pm\)1.29                 |                     |

*\(p = 0.218\) compared to Dl, \(p < 0.01\) compared to C and Normal.
**\(p < 0.01\) compared to Normal.
***\(p < 0.01\) compared to C.
\#\(p = 0.010\) compared to Dl, \(p < 0.01\) compared to C.
\##\(p < 0.01\) compared to C.

Table 1. Urethral diameter and lumen reduction of rabbits in different treated groups.

**Figure 1. Representative urethral stricture formation in retrograde urethrogram.** A Urethral stricture formation in rabbits of DH group. Note mild stricture formation at bulbar urethra. B Urethral stricture formation in rabbits of Dl group. Note moderate stricture formation at bulbar urethra. C Urethral stricture formation in rabbits of C group. Note severe stricture formation at bulb urethra.

doi:10.1371/journal.pone.0112097.g001
paclitaxel. However, according to Zhang [16], the inhibition of fibrosis formation can be attained with very low dose of paclitaxel. This may explain the contradictory effect of paclitaxel/docetaxel on fibrosis formation.

Docetaxel, as a semi-synthetic analogue of paclitaxel, is two to three times as effective as paclitaxel in promoting the assembly of mammalian brain tubulin in vitro and has a binding constant that is greater than that of paclitaxel by the same factor [23]. As a result, in this study docetaxel was used instead of paclitaxel.

As an anticancer agent, docetaxel could stabilize polymerized microtubules and enhance microtubule assembly, consequently arrests the cell cycle in the G0/G1 and G2/M phases, leading to cell death. It has been previously shown that microtubules could bind endogenous Smad2 and Smad3 and form a complex. Destabilization of the microtubules network by nocodazole, olchicine, or a tubulin mutant disrupts the complex between Smads and microtubules. TGF-β triggers dissociation of Smad2 and Smad3 form microtubules, leading phosphorylation and nuclear translocation of Smad2 and Smad3, with consequent...
activation of transcription, increasing production of extracellular matrix components. So microtubules serve as a cytoplasmic sequestering network for Smads, controlling Smads association with and phosphorylation by activated TGF-β receptor I [24]. Docetaxel stabilizes microtubules and inhibits microtubules depolymerization, suppressing Smad2 and Smad3 phosphorylation and collagen deposition [25]. That may be why docetaxel works in limiting urethral stricture formation.

In this pilot study in rabbits urethral stricture model, dose rates (0.1 versus 0.01 mg/day) of docetaxel were designed based on the reports of Zhang [16] and Sun [18] and the fact that rabbits are approximately one-half tolerant of docetaxel than rats. Considering minimal absorption by the mean of intraurethral irrigation, docetaxel was given daily. These dose rates are quite lower than used in anticancer chemotherapy. Meanwhile there is evidence to show that low-dose docetaxel had minimal, if any, detectable effects on cell proliferation [16]. According to the above analysis, we have reason to establish the assumptions that low-dose docetaxel inhibits urethral stricture formation may not via inhibition of cell proliferation, such as fibroblasts, but due to interruption on TGF-β signaling pathway. More studies are needed to confirm this hypothesis.

Conclusions

In this rabbit model, docetaxel, given by intraurethral irrigation was effective in limiting the occurrence of de novo urethral stricture. Docetaxel may become an important therapy for urethral stricture in humans. However, further studies including a larger number of animals with a longer follow up and containing more details about TGF-β/Smads signaling are needed to consolidate these conclusions.

Acknowledgments

We appreciate the help of Kang-min WANG, from department of pathology, and Song Ren, from department of general surgery in cadres ward, of the Second Affiliated Hospital of Xi’an Jiaotong University in the pathological analysis and statistical analysis, respectively.

Author Contributions

Conceived and designed the experiments: HL, DF. Performed the experiments: DF HZ. Analyzed the data: HL TC. Contributed reagents/materials/analysis tools: DF ZW. Wrote the paper: DF HL.

References

1. Lumen N, Hoebbeke P, Willemsen P, Troyer BD, Pieters R, et al. (2009) Etiology of urethral stricture disease in the 21st century. Journal of Urology 182: 983–987.
2. Waxman SW, Morey AF (2006) Management of urethral strictures. The Lancet 367: 1397–1398.
3. Greenwell T, Castle C, Andrich D, MacDonald J, Nicol D, et al. (2004) Repeat urethroplasty and the treatment of urethral stricture are neither clinically effective nor cost-effective. the Journal of Urology 172: 275–277.
4. Langston J, Robson C, Rice K, Evans L, Morey A (2009) Synchronous urethral stricture reconstruction via 1-stage ascending approach: rationale and results. Journal of Urology 181: 2161–2163.
5. Nagler A, Gefrit O, Ohana M, Priel D, Gavina O, et al. (2008) The effect of halofuginone, an inhibitor of collagen type I synthesis, on urethral stricture formation: in vivo and in vitro study in a rat model. Journal of Urology 164: 1776–1780.
6. Maziak H, Moshki I, Ghassami F (2007) Effect of mifosycin C on anterior urethral stricture recurrence after internal urethropexy. European Urology 51: 1089–1092.
7. Khera M, Boone TB, Smith CP (2004) Botulinum toxin type A: a novel approach to the treatment of recurrent urethral strictures. Journal of Urology 172: 574–575.
8. Andersen H, Duch B, Gregersen H, Nielsen J, Orskov H (2003) The effect of the somatostatin analogue lanreotide on the prevention of urethral strictures in a rabbit model. Urological Research 31: 25–31.
9. Sciarra A, Salciccia S, Albanesi L (2005) Use of cyclooxygenase-2 inhibitor for prevention of urethral strictures secondary to transurethral resection of the prostate. Urological Research 33: 1218–1222.
10. Qi Z, Bo X, Yue-jin Y, Rui-yan Z, Jian-ping L, et al. (2007) Sirolimus-eluting cobalt alloyed stents in treating patients with coronary artery disease: six-month angiographic and one-year clinical follow-up result A prospective, historically controlled, multi-center clinical study. Chinese Medical Journal 120: 353–358.
11. Xiu-Chen Z, Rong-Chong H, Bo Z, Da Y, Bin L, et al. (2010) Inflammation inhibitory effects of sirolimus and paclitaxel-eluting stents on interleukin-1β-induced coronary artery in-stent restenosis in pigs. Chinese Medical Journal 123: 2405–2409.
12. Chong T, Fu D, Li H, Zhang H, Zhang P, et al. (2011) Rapamycin Inhibits Formation of Urethral Stricture in Rabbits. The Journal of Pharmacology and Experimental Therapeutics 338: 47–52.
13. Jadzane M, Ali-El-Deen B, Ouaïaes A, Haïrèz AT, Mohsen T, et al. (2003) The use of halofuginone in limiting urethral stricture formation and recurrence: an experimental study in rabbits. Journal of Urology 170: 2049–2052.
14. Meria P, Aniđar M, Brouland JP, Teillac P, Duc AL, et al. (1999) An experimental model of bulbar urethral stricture in rabbits using endoscopic radiofrequency coagulation. Urology 53: 1054–1057.
15. Andersen H, Duch B, Nielsen J, Jeorgensen B, Ledet T (2003) An experimental model for stricture studies in the anterior urethra of the male rabbit. Urology Research 31: 363–367.
16. Zhang D, Sun J, Xian W, Liu F, Ling G, et al. (2010) Low-dose paclitaxel ameliorates renal fibrosis in rat UUO model by inhibition of TGF-β/Smad activity. Laboratory Investigation 90: 436–447.
17. Zhou J, Zhong D-W, Wang Q-W, Miao X-Y, Xu X-D (2010) Paclitaxel ameliorates fibrosis in hepatic stellate cells via inhibition of TGF-β/Smad activity. World Journal of Gastroenterology 16: 3330–3334.

18. Lin Sun, Zhang D, Liu F, Xiang X, Ling G, et al. (2011) Low-dose paclitaxel ameliorates fibrosis in the remnant kidney model by down-regulating miR-192. Journal of Pathology 225: 364–377.

19. Suk KT, Kim JW, Kim HS, Baik SK, Oh SJ, et al. (2007) Human application of a metallic stent covered with a paclitaxel-incorporated membrane for malignant biliary obstruction: multicenter pilot study. Gastrointestinal Endoscopy 66: 798–803.

20. Esmaeli B, Amin S, Valero V, Adinin R, Arbuckle R, et al. (2006) Prospective Study of Incidence and Severity of Epiphora and Canalicular Stenosis in Patients With Metastatic Breast Cancer Receiving Docetaxel. Journal of Clinical Oncology 24: 3619–3622.

21. Ostoros G, Pretz A, Fillinger J, Soltesz I, Dome B (2006) Fatal pulmonary fibrosis induced by paclitaxel: a case report and review of the literature. International Journal of Gynecology Cancer 16: 391–393.

22. Kupfer I, Balgaerie X, Courville P, Chinet P, Joly P (2003) Scleroderma-like cutaneous lesions induced by paclitaxel: a case study. Journal of the American Academy of Dermatology 48: 279–281.

23. Buey RM, Baraissain I, Jackson E, Meyer A, Giannakakou P, et al. (2005) Microtubule interactions with chemically diverse stabilizing agents: thermodynamics of binding to the paclitaxel site predicts cytotoxicity. Chemistry & Biology 12: 1289–1279.

24. Dong C, Li Z, Alvarez R, Feng X-H, Goldschmidt-Clermont PJ (2000) Microtubule binding to Smads may regulate TGF beta activity. Molecular cell 5: 27–34.

25. Liu X, Zhu S, Wang T, Hummers I, Wigley FM, et al. (2005) Paclitaxel Modulates TGF-β Signaling in Scleroderma Skin Grafts in Immunodeficient Mice. PLOS medicine 2: 1334–1342.